Lessons of Surgery and Entrepreneurship – Dr. Jonathan Gertler will be the keynote speaker at the NOME Annual Meeting 2019

NOME is very pleased to announce that Dr. Jonathan P. Gertler, CEO and co-founder of Back Bay Life Science Advisors, is this year’s keynote speaker at the NOME Annual Meeting & Startup Competition. Dr. Jonathan Gertler is a company founder, MedTech investor, and former vascular surgeon.

Jonathan P. Gertler is Partner at BioVentures Investors, and CEO and Co-Founder of Back Bay Life Science Advisors, an integrated strategy and investment firm to global life science companies and their investors. Based in Boston, with strong ties to the Nordic regions, Back Bay advises companies on some of the most complex business challenges facing the life science industry today.

A former vascular surgeon, Dr. Gertler has extensive experience advising public and private companies on decisions around investment banking and strategic growth. He speaks and writes on the topic frequently and frequently guides life science incubators, entrepreneurs and startups on growth strategy.

Dr. Gertler served for many years as an academic vascular surgeon, primarily as Associate Professor of Surgery at Harvard Medical School and at the Massachusetts General Hospital. He also founded several life science companies spanning an array of therapeutic areas, including: Antyllus Therapeutics, a development-stage biotechnology company focused on aortic diseases and Biofeedback Systems Design, a healthcare IT company developed for the wellness market. Dr. Gertler also founded Cardiovascular Technologies, which successfully exited in 2001.

In 2010, Dr. Gertler and his partner Mark King, founded Back Bay Life Science Advisors to marry an array of clinical, scientific, and business expertise and help positively shape the life science industry and improve patient care. Back Bay has a long history of strategic partnerships and close friendships with the Nordic life science ecosystem and frequently sponsors events to bring together US and Nordic companies and investors.

Over the past decade, Back Bay’s investment banking and strategy teams have handled assignments including supportive work for significant Nordic events, such as the acquisition of Wilson Therapeutics. Their transaction list includes Nordic companies such as Action Pharma, TopoTarget, and Zymenex, among many others. Back Bay teams have worked with companies backed by Nordic funds including HealthCap, Novo Seeds, Novo Ventures, LundbeckFounden, Sunstone, and Sarsia Seed.

Founded to provide biotech, pharmaceutical, and medical technology companies, from early startups to global market leaders, with financial and therapeutic strategies, Back Bay is among the very few life science consultancies that bring together approach with investment banking. Staff are trained in medicine, microbiology, business development, statistics, and have years of experience. Back Bay has completed well over 500 life science projects in aggregate.

In today’s keynote, Dr. Gertler will share learnings from experience as an entrepreneur, clinician, surgeon, and founder. With over 30 years of clinical, scientific, and business experience working with a wide range of life science companies, from medical devices, and diagnostics, to health care IT, he will give his thoughts on common pitfalls new life science companies often encounter.

We’re pleased to welcome from Boston to the NOME Annual Meeting, Jonathan P. Gertler, MD and invite our guests to connect with him for any questions at jgertler@bblsa.com.

The NOME Annual Meeting will be at Industriens Hus on the 27th of November.

Sign up for the event here and read more about the NOME program here.

Read more here:

Back Bay homepage